2024-04-15
紐交所上市公司Nuvation Bio于2024年4月10日宣布，完成以全股票交易方式收購創新生物制藥企業AnHeart Therapeutics Ltd.（“葆元醫藥”）。海問為Nuvation Bio在本次交易中擔任中國法律顧問，為客戶提供了多領域一體化的高質量服務。項目團隊由醫藥組合伙人吳婷、勞動組合伙人吳瓊以及公司組合伙人巫珊聯合組成。其他主要團隊成員還包括潘冰、王旭穎、陳青青、龍小寧。
Nuvation Bio, a New York Stock Exchange listed company, announced on April 10 2024 the completion of acquisition of AnHeart Therapeutics Ltd. (“AnHeart”), an innovative biotech company, in an all-stock transaction. Haiwen & Partners acted as PRC legal counsel to Nuvation Bio in this transaction, and has provided integrated and high-quality legal services to the client in this transaction. The Haiwen team includes Life Science Partner Wu Ting (Tina Wu), Labor Law Partner Wu Qiong and Corporate Partner Wu Shan. Other key team members include Pan Bing, Wang Xuying, Chen Qingqing and Long Xiaoning.
收購完成后，Nuvation Bio目前擁有葆元醫藥的全部資產，包括葆元醫藥主要管線產品Taletrectinib。Taletrectinib是治療ROS1融合陽性非小細胞肺癌的下一代ROS1抑制劑，目前正處于關鍵性II期試驗，包括在中國開展的TRUST-I（NCT04395677）試驗和TRUST-II (NCT04919811)，一項全球性關鍵試驗。Taletrectinib已獲得美國食品藥品監督管理局（FDA）和中國國家藥品監督管理局（NMPA）授予的突破性療法認定，NMPA已受理并授予Taletrectinib新藥優先審評資格。Nuvation Bio創始人David Hung表示，Taletrectinib具有同類最佳的潛在優勢，可以克服現有療法的顯著局限性，Nuvation Bio將在葆元醫藥已有研發進展基礎上再接再厲。
With the acquisition’s completion, Nuvation Bio now owns all of AnHeart’s assets including AnHeart’s lead asset Taletrectinib. Taletrectinib is a next-generation ROS1-inhibitor currently in pivotal Phase II trials for ROS1-positive non-small cell lung cancer (NSCLC), including TRUST-I (NCT04395677) in China and TRUST-II (NCT04919811), a global pivotal study. Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA). China NMPA has accepted and granted Priority Review Designation to New Drug Applications for Taletrectinib. The Founder of Nuvation Bio, David Hung, said that Taletrectinib has a potentially best-in-class profile that may overcome the significant limitations of existing therapies and Nuvation Bio intends to build on the progress that AnHeart team made to date.
Nuvation Bio是一家成立于2018年的美國生物制藥公司，專注于開發腫瘤領域差異化的新型候選療法，2021年實現在紐交所上市。其產品管線包括處于臨床階段的溴結構域和超末端結構域（BET）抑制劑，以及新型小分子藥物共軛物（DDC）平臺中的臨床候選藥物。
Nuvation Bio, founded in 2018, is a US-based biopharmaceutical company developing differentiated and novel therapeutic candidates in oncology and listed on the New York Stock Exchange in 2021. Nuvation Bio’s pipeline includes a clinical stage bromodomain and extra-terminal (BET) inhibitor program and a clinical candidate from the novel, small molecule drug-drug conjugate (DDC) platform.
葆元醫藥由王鈞源博士、顏冰博士和鄭利華博士于2018年聯合創立，是一家致力于為癌癥患者開發新一代精準療法的生物制藥集團公司，資產包括ROS1抑制劑Taletrectinib和mIDH1抑制劑Safusidenib。
AnHeart Therapeutics, co-founded in 2018 by Dr. Wang Junyuan, Dr. Yan Bing and Dr. Zheng Lihua, is a biotech company developing novel precision therapies for people with cancer, with assets including the ROS1-inhibitor Taletrectinib and the mIDH1-inhibitor Safusidenib.
紐交所上市公司Nuvation Bio于2024年4月10日宣布，完成以全股票交易方式收購創新生物制藥企業AnHeart Therapeutics Ltd.（“葆元醫藥”）。海問為Nuvation Bio在本次交易中擔任中國法律顧問，為客戶提供了多領域一體化的高質量服務。項目團隊由醫藥組合伙人吳婷、勞動組合伙人吳瓊以及公司組合伙人巫珊聯合組成。其他主要團隊成員還包括潘冰、王旭穎、陳青青、龍小寧。
Nuvation Bio, a New York Stock Exchange listed company, announced on April 10 2024 the completion of acquisition of AnHeart Therapeutics Ltd. (“AnHeart”), an innovative biotech company, in an all-stock transaction. Haiwen & Partners acted as PRC legal counsel to Nuvation Bio in this transaction, and has provided integrated and high-quality legal services to the client in this transaction. The Haiwen team includes Life Science Partner Wu Ting (Tina Wu), Labor Law Partner Wu Qiong and Corporate Partner Wu Shan. Other key team members include Pan Bing, Wang Xuying, Chen Qingqing and Long Xiaoning.
收購完成后，Nuvation Bio目前擁有葆元醫藥的全部資產，包括葆元醫藥主要管線產品Taletrectinib。Taletrectinib是治療ROS1融合陽性非小細胞肺癌的下一代ROS1抑制劑，目前正處于關鍵性II期試驗，包括在中國開展的TRUST-I（NCT04395677）試驗和TRUST-II (NCT04919811)，一項全球性關鍵試驗。Taletrectinib已獲得美國食品藥品監督管理局（FDA）和中國國家藥品監督管理局（NMPA）授予的突破性療法認定，NMPA已受理并授予Taletrectinib新藥優先審評資格。Nuvation Bio創始人David Hung表示，Taletrectinib具有同類最佳的潛在優勢，可以克服現有療法的顯著局限性，Nuvation Bio將在葆元醫藥已有研發進展基礎上再接再厲。
With the acquisition’s completion, Nuvation Bio now owns all of AnHeart’s assets including AnHeart’s lead asset Taletrectinib. Taletrectinib is a next-generation ROS1-inhibitor currently in pivotal Phase II trials for ROS1-positive non-small cell lung cancer (NSCLC), including TRUST-I (NCT04395677) in China and TRUST-II (NCT04919811), a global pivotal study. Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA). China NMPA has accepted and granted Priority Review Designation to New Drug Applications for Taletrectinib. The Founder of Nuvation Bio, David Hung, said that Taletrectinib has a potentially best-in-class profile that may overcome the significant limitations of existing therapies and Nuvation Bio intends to build on the progress that AnHeart team made to date.
Nuvation Bio是一家成立于2018年的美國生物制藥公司，專注于開發腫瘤領域差異化的新型候選療法，2021年實現在紐交所上市。其產品管線包括處于臨床階段的溴結構域和超末端結構域（BET）抑制劑，以及新型小分子藥物共軛物（DDC）平臺中的臨床候選藥物。
Nuvation Bio, founded in 2018, is a US-based biopharmaceutical company developing differentiated and novel therapeutic candidates in oncology and listed on the New York Stock Exchange in 2021. Nuvation Bio’s pipeline includes a clinical stage bromodomain and extra-terminal (BET) inhibitor program and a clinical candidate from the novel, small molecule drug-drug conjugate (DDC) platform.
葆元醫藥由王鈞源博士、顏冰博士和鄭利華博士于2018年聯合創立，是一家致力于為癌癥患者開發新一代精準療法的生物制藥集團公司，資產包括ROS1抑制劑Taletrectinib和mIDH1抑制劑Safusidenib。
AnHeart Therapeutics, co-founded in 2018 by Dr. Wang Junyuan, Dr. Yan Bing and Dr. Zheng Lihua, is a biotech company developing novel precision therapies for people with cancer, with assets including the ROS1-inhibitor Taletrectinib and the mIDH1-inhibitor Safusidenib.
京ICP備05019364號-1 
京公網安備110105011258